The purpose of the Unit is to inactivate viruses on medical instruments, which are not subject to disinfection at high temperatures or with the use of aggressive chemicals. The Unit prevents infection of patients with hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) via medical instruments while undergoing medical procedures. The Unit for inactivation of viruses on medical instruments can be used in medical institutions – public and private hospitals, clinics and medical offices of various profiles and levels.
Patents from the patent offices of Uzbekistan, Eurasia, USA and China are received for the Invention of Unit for inactivation of viruses, bacteria, fungi and endospores on medical instruments.
- On inactivation of polio virus vaccine strains – loss of cytopathogenic properties
- On inactivation of bacteriophages S.typhi – loss of ability to phage S.typhi
- On inactivation of influenza viruses – loss of cytopathogenic properties
- On inactivation of the Crimean Congo viruses hemorrhagic fever – loss of cytopathogenic properties
- On inactivation of the human immunodeficiency virus (HIV) – loss of lymphotropy
- On inactivation of hepatitis C and B virus – loss of lymphotropy
The State Patent Office of the Republic of Uzbekistan issued a patent on the method for detecting and assessing the viability of lymphotropic viruses, registered in the State Register of utility models of the Republic of Uzbekistan in Tashkent under IAP 04903 dated 06/18/2012.
Currently, European and Eurasian Patent Offices, as well as patent offices of the following countries: China, Korea, Africa, USA, Israel, UAE, India, have accepted patent applications for the invention (method for assessing the viability of lymphotropic viruses).